Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.01. | Syra Health files for $75M mixed securities shelf | 1 | Seeking Alpha | ||
17.01. | Syra Health Corp - 8-K, Current Report | - | SEC Filings | ||
07.01. | Why Is Syra Health Stock Surging Today? | 1 | Benzinga.com | ||
07.01. | Syra Health secures contracts in education, healthcare sectors | 1 | Investing.com | ||
07.01. | Syra Health sichert sich Verträge im Bildungs- und Gesundheitssektor | 1 | Investing.com Deutsch | ||
29.10.24 | Syra Health Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
SYRA HEALTH Aktie jetzt für 0€ handeln | |||||
29.10.24 | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
29.10.24 | Syra Health GAAP EPS of -$0.06, revenue of $2.25M | 2 | Seeking Alpha | ||
29.10.24 | Syra Health Delivers Third Quarter 2024 Financial Results | 136 | PR Newswire | Achieved Net Revenue of $2.3 million, ~42% Growth Over the Prior Year Quarter
Gross Margins Increased Following Shift in Operational Strategy
Net Loss Narrowed to... ► Artikel lesen | |
28.10.24 | Earnings Preview: Syra Health | 2 | Benzinga.com | ||
21.10.24 | Syra Health faces Nasdaq delisting over share price | 1 | Investing.com | ||
21.10.24 | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
09.10.24 | Syra Health sichert sich mehrere staatliche Gesundheitsverträge | 1 | Investing.com Deutsch | ||
13.09.24 | Syra Health completes $2.1 million public offering | 1 | Investing.com | ||
13.09.24 | Syra Health schließt öffentliches Aktienangebot über 2,1 Millionen Dollar ab | - | Investing.com Deutsch | ||
13.09.24 | Syra Health CFO and COO Priya Prasad buys shares worth $13,256, sells for $10,143 | 1 | Investing.com | ||
12.09.24 | Why Syra Health Stock Is Down 50% Today | 1 | Benzinga.com | ||
12.09.24 | Syra Health stock dips after pricing $2.1M securities offering | 3 | Seeking Alpha | ||
11.09.24 | Pre-market Movers: Quhuo, Telesis Bio, Designer Brands, BIO-key International, Syra Health | 620 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).In the Green Quhuo Limited (QH) is up over 92% at $2.56.
BIO-key... ► Artikel lesen | |
08.08.24 | Syra Health Announces Second Quarter 2024 Financial Results, Led by Strong Revenue Growth of 101% | 120 | PR Newswire | Conference call will be held today, Thursday, August 8 at 9:00 am ET
CARMEL, Ind., Aug. 8, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,140 | +0,57 % | XETR CA81732W1041: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME Waehrung/Currency ISIN BIS/UNTILSERNOVA CORP. EUR... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,737 | -5,51 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care | ||
PING AN HEALTHCARE | 0,779 | +0,62 % | PA GOODDOCTOR (01833): DISCLOSURE OF DEALINGS UNDER RULE 22 OF THE TAKEOVERS CODE | ||
MOUNTAIN VALLEY MD | 0,016 | -13,83 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,635 | -3,79 % | Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results | SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development... ► Artikel lesen | |
CYTOSORBENTS | 0,931 | -9,44 % | CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue | Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor... ► Artikel lesen | |
VERU | 0,518 | +2,27 % | Veru Inc.: Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction | -- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 0,884 | +2,79 % | Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif.... ► Artikel lesen | |
VOLITIONRX | 0,577 | 0,00 % | VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for
Friday, November 15 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., Nov. 14, 2024... ► Artikel lesen | |
EKSO BIONICS | 0,500 | -9,75 % | Ekso Bionics Holdings, Inc.: NSM Named Exclusive Distributor of Ekso Indego Personal Within the CRT Industry | ||
IMUNON | 0,840 | -0,59 % | Imunon, Inc.: IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer | Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
BEYOND AIR | 0,380 | -5,00 % | Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update | Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international... ► Artikel lesen | |
AVINGER | 0,455 | 0,00 % | Avinger Inc - 8-K, Current Report | ||
NOVACYT | 0,602 | +0,33 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights | ||
AROVELLA THERAPEUTICS | 0,104 | 0,00 % | XFRA E4NA: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAROVELLA THERAPEUTICS... ► Artikel lesen |